HCC-话题@MedSci

#HCC#

114篇内容 | 4661人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259490, encodeId=a46b1259490ff, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, objectType=article, longId=121557, objectId=f7f212155e0e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7f212155e0e, replyNumber=0, likeNumber=71, createdTime=2017-11-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7f212155e0e, moduleTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7f212155e0e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259489, encodeId=0c6612594897f, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：抗血小板治疗会降低慢性乙肝患者HCC风险吗？, objectType=article, longId=120963, objectId=773d12096392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=773d12096392, replyNumber=0, likeNumber=57, createdTime=2017-11-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=773d12096392, moduleTitle=Hepatology：抗血小板治疗会降低慢性乙肝患者HCC风险吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=773d12096392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259488, encodeId=a3b712594883d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Sci Rep：研究进一步揭示HCC耐药性的潜在机制, objectType=article, longId=113694, objectId=c1a511369488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1a511369488, replyNumber=0, likeNumber=84, createdTime=2017-09-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1a511369488, moduleTitle=Sci Rep：研究进一步揭示HCC耐药性的潜在机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1a511369488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259487, encodeId=07f3125948ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：HCC患者接受索拉非尼治疗获得完全应答及其与皮肤学反应的关系, objectType=article, longId=112896, objectId=2e4311289681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e4311289681, replyNumber=0, likeNumber=59, createdTime=2017-09-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e4311289681, moduleTitle=Hepatology：HCC患者接受索拉非尼治疗获得完全应答及其与皮肤学反应的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e4311289681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259486, encodeId=2392125948641, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, objectType=article, longId=87963, objectId=6f318e96342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f318e96342, replyNumber=0, likeNumber=0, createdTime=2017-01-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f318e96342, moduleTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f318e96342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259485, encodeId=fdc71259485fe, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Ann Surg：HCC术后复发的原因在此！, objectType=article, longId=87882, objectId=dbf18e8822b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf18e8822b, replyNumber=0, likeNumber=85, createdTime=2017-01-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf18e8822b, moduleTitle=Ann Surg：HCC术后复发的原因在此！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbf18e8822b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259484, encodeId=08e11259484e5, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Sci Rep：周伟平等人发现HCC转移新机制, objectType=article, longId=83664, objectId=f72d836640a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72d836640a, replyNumber=0, likeNumber=61, createdTime=2016-12-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72d836640a, moduleTitle=Sci Rep：周伟平等人发现HCC转移新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72d836640a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259483, encodeId=3ed412594831a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：核苷（酸）类似物治疗可降低HBV相关性HCC的复发率, objectType=article, longId=69264, objectId=6ce26926482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ce26926482, replyNumber=0, likeNumber=66, createdTime=2016-05-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ce26926482, moduleTitle=Hepatology：核苷（酸）类似物治疗可降低HBV相关性HCC的复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ce26926482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259482, encodeId=5cac12594828e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=存在HCC史的患者近1/3在接受DAA治疗后复发, objectType=article, longId=66522, objectId=41656652216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41656652216, replyNumber=0, likeNumber=80, createdTime=2016-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41656652216, moduleTitle=存在HCC史的患者近1/3在接受DAA治疗后复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41656652216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259481, encodeId=8e961259481c4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：系统回顾基于碘油的TACE治疗HCC的有效性和安全性, objectType=article, longId=64422, objectId=1b81644224a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b81644224a, replyNumber=0, likeNumber=81, createdTime=2016-03-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b81644224a, moduleTitle=Hepatology：系统回顾基于碘油的TACE治疗HCC的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b81644224a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259480, encodeId=7dab125948060, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：他汀类药物可帮助HCV患者降低肝硬化和HCC风险, objectType=article, longId=64398, objectId=79bb643989a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79bb643989a, replyNumber=0, likeNumber=55, createdTime=2016-03-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79bb643989a, moduleTitle=Hepatology：他汀类药物可帮助HCV患者降低肝硬化和HCC风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79bb643989a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259479, encodeId=58da12594e93e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：慢乙肝患者发生了自发性HBsAg清除后，还需要进行HCC监测吗？, objectType=article, longId=44855, objectId=c021448557a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c021448557a, replyNumber=0, likeNumber=77, createdTime=2015-01-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c021448557a, moduleTitle=J Hepatol：慢乙肝患者发生了自发性HBsAg清除后，还需要进行HCC监测吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c021448557a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259478, encodeId=b85512594e829, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力, objectType=article, longId=41810, objectId=d76d4181080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d76d4181080, replyNumber=0, likeNumber=60, createdTime=2014-10-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d76d4181080, moduleTitle=Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d76d4181080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259477, encodeId=6ea012594e77d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=2012 CHCC 血管炎新分类标准启示, objectType=article, longId=38493, objectId=03b43849354, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03b43849354, replyNumber=0, likeNumber=64, createdTime=2014-08-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03b43849354, moduleTitle=2012 CHCC 血管炎新分类标准启示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03b43849354)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259476, encodeId=92db12594e680, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：手术与射频消融治疗无门脉高压的HCC效果相似, objectType=article, longId=33354, objectId=26d633354c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d633354c9, replyNumber=0, likeNumber=68, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d633354c9, moduleTitle=EASL 2014：手术与射频消融治疗无门脉高压的HCC效果相似, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26d633354c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259475, encodeId=f0ae12594e546, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：钆塞酸为造影剂的MRI对HCC分期可改善患者预后, objectType=article, longId=33353, objectId=a8a033353b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8a033353b4, replyNumber=0, likeNumber=83, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8a033353b4, moduleTitle=EASL 2014：钆塞酸为造影剂的MRI对HCC分期可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8a033353b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259474, encodeId=69bf12594e437, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估, objectType=article, longId=33350, objectId=08053335022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08053335022, replyNumber=0, likeNumber=72, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08053335022, moduleTitle=EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08053335022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259473, encodeId=612012594e31d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：BCLC-B亚分类或对HCC患者预后有一定价值, objectType=article, longId=33349, objectId=cbec3334967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbec3334967, replyNumber=0, likeNumber=83, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbec3334967, moduleTitle=EASL 2014：BCLC-B亚分类或对HCC患者预后有一定价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbec3334967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259472, encodeId=c00812594e2ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：肝移植供体因素应纳入移植术后HCC复发因素中, objectType=article, longId=33347, objectId=2a1b3334e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a1b3334e0a, replyNumber=0, likeNumber=80, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a1b3334e0a, moduleTitle=EASL 2014：肝移植供体因素应纳入移植术后HCC复发因素中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a1b3334e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259471, encodeId=c18212594e177, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：LSM-HCC评分可准确预测慢乙肝患者肝癌发生风险, objectType=article, longId=25617, objectId=36472561e7d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36472561e7d, replyNumber=0, likeNumber=80, createdTime=2013-10-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36472561e7d, moduleTitle=J Hepatol：LSM-HCC评分可准确预测慢乙肝患者肝癌发生风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36472561e7d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新

2017-11-29

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：抗血小板治疗会降低慢性乙肝患者HCC风险吗？

2017-11-23

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Sci Rep：研究进一步揭示HCC耐药性的潜在机制

2017-09-23

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：HCC患者接受索拉非尼治疗获得完全应答及其与皮肤学反应的关系

2017-09-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功

2017-01-24

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Ann Surg：HCC术后复发的原因在此！

2017-01-22

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Sci Rep：周伟平等人发现HCC转移新机制

2016-12-08

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：核苷（酸）类似物治疗可降低HBV相关性HCC的复发率

2016-05-27

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

存在HCC史的患者近1/3在接受DAA治疗后复发

2016-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：系统回顾基于碘油的TACE治疗HCC的有效性和安全性

2016-03-09

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：他汀类药物可帮助HCV患者降低肝硬化和HCC风险

2016-03-08

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：慢乙肝患者发生了自发性HBsAg清除后，还需要进行HCC监测吗？

2015-01-01

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力

2014-10-30

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

2012 CHCC 血管炎新分类标准启示

2014-08-02

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：手术与射频消融治疗无门脉高压的HCC效果相似

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：钆塞酸为造影剂的MRI对HCC分期可改善患者预后

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：BCLC-B亚分类或对HCC患者预后有一定价值

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：肝移植供体因素应纳入移植术后HCC复发因素中

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：LSM-HCC评分可准确预测慢乙肝患者肝癌发生风险

2013-10-23

科室
- - 订阅+
  - 更多科室
工具
服务